このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kintor Pharmaceutical バランスシートの健全性

財務の健全性基準チェック /46

Kintor Pharmaceuticalの総株主資本はCN¥458.1M 、総負債はCN¥247.1Mで、負債比率は53.9%となります。総資産と総負債はそれぞれCN¥869.2MとCN¥411.1Mです。

主要情報

53.9%

負債資本比率

CN¥247.10m

負債

インタレスト・カバレッジ・レシオ	n/a
現金	CN¥458.05m
エクイティ	CN¥458.11m
負債合計	CN¥411.12m
総資産	CN¥869.23m

財務の健全性に関する最新情報

Recent updates

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Nov 16

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Apr 28

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Dec 06

Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?

Sep 01

Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings

Feb 17

What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?

Dec 23

財務状況分析

短期負債: 9939の短期資産 ( CN¥472.6M ) が短期負債 ( CN¥224.7M ) を超えています。

長期負債: 9939の短期資産 ( CN¥472.6M ) が長期負債 ( CN¥186.4M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 9939総負債よりも多くの現金を保有しています。

負債の削減: 9939の負債対資本比率は、過去 5 年間で25.8%から53.9%に増加しました。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: 9939は、現在のフリーキャッシュフローに基づき、1 年以上にわたって十分なキャッシュランウェイを有しています。

キャッシュランウェイの予測: 9939は、フリーキャッシュフローが毎年19.6 % の歴史的率で減少し続ける場合、キャッシュランウェイが 1 年未満になります。

Kintor Pharmaceutical バランスシートの健全性

財務の健全性 基準チェック /46

主要情報

財務の健全性に関する最新情報

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?

Recent updates

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New major risk - Share price stability

Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA

Founder recently bought HK$774k worth of stock

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

New minor risk - Share price stability

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

New major risk - Financial position

Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Insider recently sold HK$2.6m worth of stock

Insider recently sold HK$42m worth of stock

New major risk - Revenue and earnings growth

Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023

Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China

Insider recently sold HK$12m worth of stock

Forecast to breakeven in 2023

Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million.

Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China

Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc

Consensus revenue estimates fall by 98%

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us

Key Executive recently sold HK$5.7m worth of stock

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022

Insider recently sold HK$60m worth of stock

Kintor Pharmaceutical Limited Announces Board Changes

Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

Forecast breakeven date pushed back to 2023

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19

Forecast breakeven date pushed back to 2023

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients

Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited Announces Executive Changes

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne

Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Deputy GM & Joint Company Secretary Jie Chen has left the company

Non-Executive Director Wei Zhang has left the company

Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826

Kintor Pharmaceutical Limited Announces the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized Covid-19 Patients

Non-Executive Director recently bought HK$4.3m worth of stock

Kintor Pharmaceutical Limited Announces Primary Endpoint of Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia

Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

Kintor Pharmaceutical Limited Announces Investigational New Drug (IND) Clearance by the US FDA for GT20029 for Androgenetic Alopecia and Acne Vulgaris

Kintor Pharmaceutical Announces FDA Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US

Consensus forecasts updated

Kintor Pharmaceutical Limited Receives Approval from Razilian Health Regulatory Agency in the Phase III Clinical Trial of Proxalutamide for Treatment of Male Patients with Mild to Moderate COVID-19 Illness

FDA Approves the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalised COVID-19 Patients

Non-Executive Director has left the company

Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S

Kintor Pharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

財務の健全性基準チェック /46